Meta Platforms
META
Oracle
ORCL
Strategy
MSTR
4
Toll Brothers
TOL
5
MARA Holdings
MARA
US Stock MarketDetailed Quotes
HUMA Humacyte
- 1.310
- -0.100-7.09%
Close May 2 16:00 ET
- 1.300
- -0.010-0.76%
Post 19:57 ET
203.21MMarket Cap-1.04P/E (TTM)
1.420High1.280Low8.03MVolume1.410Open1.410Pre Close10.70MTurnover6.51%Turnover RatioLossP/E (Static)155.12MShares9.97052wk High-3.85P/B161.72MFloat Cap1.15052wk Low--Dividend TTM123.45MShs Float17.450Historical High--Div YieldTTM9.93%Amplitude1.150Historical Low1.332Avg Price1Lot Size
About Humacyte Company
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.
Company Profile
SymbolHUMA
Company NameHumacyte
Listing DateDec 1, 2020
Founded2004
CEODr. Laura E. Niklason, M.D.,PhD
MarketNASDAQ
Employees220
Fiscal Year Ends12-31
Address2525 East North Carolina Highway 54
CityDurham
ProvinceNorth Carolina
CountryUnited States of America
Zip Code27713
Phone1-919-313-9633
Websitehttp://humacyte.com
Company Executives
- Name
- Position
- Salary
- Dr. Laura E. Niklason, M.D.,PhD
- President, Chief Executive Officer and Director
- 905.44K
- William John Scheessele
- Chief Commercial Officer
- --
- Shamik J. Parikh
- Chief Medical Officer
- --
- Dale A. Sander
- Principal Accounting Officer, Chief Financial Officer, Chief Corporate Development Officer and Treasurer
- 704.19K
- Dr. Yang Cao
- Chief Regulatory Officer
- --
- Dr. Heather Prichard
- Chief Operating Officer
- 653.21K
- Kathleen Sebelius
- Chairman of the Board
- 356.00K
- Brady W. Dougan
- Director
- 331.00K
- Diane Seimetz, PhD
- Independent Director
- 331.00K
- Todd M. Pope
- Independent Director
- 336.00K
- Michael T. Constantino
- Independent Director
- 338.50K
- C. Bruce Green, M.D.
- Independent Director
- 331.00K
- Dr. Susan Richards Windham-Bannister, PhD
- Independent Director
- 331.00K
- Dr. Max Wallace, J.D.
- Independent Director
- 336.00K
- Dr. Keith Anthony Jones, M.D.
- Independent Director
- 449.25K
- Dr. John P. Bamforth
- Independent Director
- 449.25K
- Dr. Emery N. Brown, M.D.,PhD
- Independent Director
- 331.00K
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call